Published in J Mol Cell Cardiol on August 19, 2010
Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell (2012) 3.33
Paracrine effect of mesenchymal stem cells derived from human adipose tissue in bone regeneration. PLoS One (2014) 1.72
Reverse remodeling in heart failure--mechanisms and therapeutic opportunities. Nat Rev Cardiol (2011) 1.49
Human mesenchymal stem cells reprogram adult cardiomyocytes toward a progenitor-like state through partial cell fusion and mitochondria transfer. Stem Cells (2011) 1.38
"String theory" of c-kit(pos) cardiac cells: a new paradigm regarding the nature of these cells that may reconcile apparently discrepant results. Circ Res (2015) 1.29
The heme oxygenase 1 inducer (CoPP) protects human cardiac stem cells against apoptosis through activation of the extracellular signal-regulated kinase (ERK)/NRF2 signaling pathway and cytokine release. J Biol Chem (2012) 1.24
The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol (2012) 1.10
The relative contribution of paracine effect versus direct differentiation on adipose-derived stem cell transplantation mediated cardiac repair. PLoS One (2013) 1.09
Concise review: the role of clinical trials in deciphering mechanisms of action of cardiac cell-based therapy. Stem Cells Transl Med (2011) 1.09
Coronary artery ligation and intramyocardial injection in a murine model of infarction. J Vis Exp (2011) 1.03
Translating stem cell research to cardiac disease therapies: pitfalls and prospects for improvement. J Am Coll Cardiol (2014) 1.02
Mesenchymal stem cells as a potent cell source for articular cartilage regeneration. World J Stem Cells (2014) 1.01
Stem cells as drug delivery methods: application of stem cell secretome for regeneration. Adv Drug Deliv Rev (2014) 0.99
Heme oxygenase-1 is required for angiogenic function of bone marrow-derived progenitor cells: role in therapeutic revascularization. Antioxid Redox Signal (2014) 0.98
Functional consequences of a tissue-engineered myocardial patch for cardiac repair in a rat infarct model. Tissue Eng Part A (2014) 0.97
In vivo therapeutic potential of mesenchymal stromal cells depends on the source and the isolation procedure. Stem Cell Reports (2015) 0.97
Hypoxic conditioning enhances the angiogenic paracrine activity of human adipose-derived stem cells. Stem Cells Dev (2013) 0.96
Cardiac stem cell therapy for cardiac repair. Curr Treat Options Cardiovasc Med (2014) 0.96
Exploiting paracrine mechanisms of tissue regeneration to repair damaged organs. Transplant Res (2013) 0.96
Mesenchymal stem cells conditioned with glucose depletion augments their ability to repair-infarcted myocardium. J Cell Mol Med (2012) 0.95
Costimulation-adhesion blockade is superior to cyclosporine A and prednisone immunosuppressive therapy for preventing rejection of differentiated human embryonic stem cells following transplantation. Stem Cells (2013) 0.95
Potential of cardiac stem/progenitor cells and induced pluripotent stem cells for cardiac repair in ischaemic heart disease. Clin Sci (Lond) (2013) 0.95
Bone marrow progenitor cell therapy-mediated paracrine regulation of cardiac miRNA-155 modulates fibrotic response in diabetic hearts. PLoS One (2013) 0.93
Excitation-contraction coupling in ventricular myocytes is enhanced by paracrine signaling from mesenchymal stem cells. J Mol Cell Cardiol (2012) 0.93
Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur Heart J (2016) 0.91
Rosuvastatin enhances angiogenesis via eNOS-dependent mobilization of endothelial progenitor cells. PLoS One (2013) 0.90
Lung stem and progenitor cells. Respiration (2013) 0.90
Cardiac regeneration: epicardial mediated repair. Proc Biol Sci (2015) 0.88
Early outgrowth cells release soluble endocrine antifibrotic factors that reduce progressive organ fibrosis. Stem Cells (2013) 0.88
Human endometrial stem cells confer enhanced myocardial salvage and regeneration by paracrine mechanisms. J Cell Mol Med (2013) 0.87
Preconditioning Human Cardiac Stem Cells with an HO-1 Inducer Exerts Beneficial Effects After Cell Transplantation in the Infarcted Murine Heart. Stem Cells (2015) 0.87
Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction. Biomaterials (2015) 0.86
Cardiac regeneration using pluripotent stem cells--progression to large animal models. Stem Cell Res (2014) 0.86
Molecular pathogenesis of myocardial remodeling and new potential therapeutic targets in chronic heart failure. Ital J Pediatr (2012) 0.85
HASF is a stem cell paracrine factor that activates PKC epsilon mediated cytoprotection. J Mol Cell Cardiol (2013) 0.84
Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair. Circ Res (2013) 0.84
Biomimetic scaffolds for regeneration of volumetric muscle loss in skeletal muscle injuries. Acta Biomater (2015) 0.84
Diabetic impairment of C-kit bone marrow stem cells involves the disorders of inflammatory factors, cell adhesion and extracellular matrix molecules. PLoS One (2011) 0.84
Angiogenic therapy for cardiac repair based on protein delivery systems. Heart Fail Rev (2012) 0.83
Stem cell stimulation of endogenous myocyte regeneration. Clin Sci (Lond) (2013) 0.83
Paracrine action of mesenchymal stem cells revealed by single cell gene profiling in infarcted murine hearts. PLoS One (2015) 0.83
The secretome of endothelial progenitor cells promotes brain endothelial cell activity through PI3-kinase and MAP-kinase. PLoS One (2014) 0.82
Ischemia/Reperfusion injury protection by mesenchymal stem cell derived antioxidant capacity. Stem Cells Dev (2013) 0.82
Bone marrow mononuclear cells induce beneficial remodeling and reduce diastolic dysfunction in the left ventricle of hypertensive SS/MCWi rats. Physiol Genomics (2012) 0.81
Myocardial regeneration of the failing heart. Heart Fail Rev (2013) 0.81
Cardiac tissue engineering: a reflection after a decade of hurry. Front Physiol (2014) 0.81
Synergism of matrix stiffness and vascular endothelial growth factor on mesenchymal stem cells for vascular endothelial regeneration. Tissue Eng Part A (2014) 0.80
Towards comprehensive cardiac repair and regeneration after myocardial infarction: Aspects to consider and proteins to deliver. Biomaterials (2015) 0.80
Inhibition of Wnt6 by Sfrp2 regulates adult cardiac progenitor cell differentiation by differential modulation of Wnt pathways. J Mol Cell Cardiol (2015) 0.79
REVIVE Trial: Retrograde Delivery of Autologous Bone Marrow in Patients With Heart Failure. Stem Cells Transl Med (2015) 0.79
The Regenerative Role of the Fetal and Adult Stem Cell Secretome. J Clin Med (2013) 0.79
Characterization of contracting cardiomyocyte colonies in the primary culture of neonatal rat myocardial cells: a model of in vitro cardiomyogenesis. Cell Cycle (2014) 0.79
Small intestinal submucosa-derived extracellular matrix bioscaffold significantly enhances angiogenic factor secretion from human mesenchymal stromal cells. Stem Cell Res Ther (2015) 0.78
Suicide gene-mediated sequencing ablation revealed the potential therapeutic mechanism of induced pluripotent stem cell-derived cardiovascular cell patch post-myocardial infarction. Antioxid Redox Signal (2014) 0.78
Regenerative therapies in electrophysiology and pacing: introducing the next steps. J Interv Card Electrophysiol (2010) 0.78
The role of tissue engineering and biomaterials in cardiac regenerative medicine. Can J Cardiol (2014) 0.78
The human amniotic fluid stem cell secretome effectively counteracts doxorubicin-induced cardiotoxicity. Sci Rep (2016) 0.77
"Second-generation" stem cells for cardiac repair. World J Stem Cells (2015) 0.77
Neuregulin-1β induces mature ventricular cardiac differentiation from induced pluripotent stem cells contributing to cardiac tissue repair. Stem Cells Dev (2014) 0.77
Redox signaling in cardiac renewal. Antioxid Redox Signal (2014) 0.77
Direct cardiomyocyte reprogramming: a new direction for cardiovascular regenerative medicine. Cold Spring Harb Perspect Med (2013) 0.77
Sensory neuropathy hampers nociception-mediated bone marrow stem cell release in mice and patients with diabetes. Diabetologia (2015) 0.76
Autologous immuno magnetically selected CD133+ stem cells in the treatment of no-option critical limb ischemia: clinical and contrast enhanced ultrasound assessed results in eight patients. J Transl Med (2015) 0.76
Pathological Left Ventricular Hypertrophy and Stem Cells: Current Evidence and New Perspectives. Stem Cells Int (2015) 0.76
Noninvasive imaging of myocyte apoptosis following application of a stem cell-engineered delivery platform to acutely infarcted myocardium. J Nucl Med (2013) 0.76
Mesenchymal Stem Cell Seeding of Porcine Small Intestinal Submucosal Extracellular Matrix for Cardiovascular Applications. PLoS One (2016) 0.76
Transcriptional changes in bone marrow stromal cells of patients with heart failure. Cell Cycle (2014) 0.76
Cardiac migration of endogenous mesenchymal stromal cells in patients with inflammatory cardiomyopathy. Mediators Inflamm (2015) 0.75
Stem cell therapy for CHD: towards translation. Cardiol Young (2015) 0.75
Secreted Endothelial Cell Factors Immobilized on Collagen Scaffolds Enhance the Recipient Endothelial Cell Environment. Biores Open Access (2016) 0.75
Cardiosphere-derived cells from pediatric end-stage heart failure patients have enhanced functional activity due to the heat shock response regulating the secretome. Stem Cells (2015) 0.75
Dose-dependency and reversibility of radiation-induced injury in cardiac explant-derived cells of mice. Sci Rep (2017) 0.75
Cardiac Regeneration using Growth Factors: Advances and Challenges. Arq Bras Cardiol (2016) 0.75
A Gingiva-Derived Mesenchymal Stem Cell-Laden Porcine Small Intestinal Submucosa Extracellular Matrix Construct Promotes Myomucosal Regeneration of the Tongue. Tissue Eng Part A (2016) 0.75
Exosomes Generated From iPSC-Derivatives: New Direction for Stem Cell Therapy in Human Heart Diseases. Circ Res (2017) 0.75
Transplantation of Epigenetically Modified Adult Cardiac c-Kit+ Cells Retards Remodeling and Improves Cardiac Function in Ischemic Heart Failure Model. Stem Cells Transl Med (2015) 0.75
Non-invasive in vivo imaging of cardiac stem/progenitor cell biodistribution and retention after intracoronary and intramyocardial delivery in a swine model of chronic ischemia reperfusion injury. J Transl Med (2017) 0.75
Inhibition of Oct 3/4 mitigates the cardiac progenitor-derived myocardial repair in infarcted myocardium. Stem Cell Res Ther (2015) 0.75
Cardiac stem cell therapy: Have we put too much hype in which cell type to use? Heart Fail Rev (2015) 0.75
Effects of Mesenchymal Stem Cell Derivatives on Hematopoiesis and Hematopoietic Stem Cells. Adv Pharm Bull (2017) 0.75
Myocardial Reparative Properties of Cardiac Mesenchymal Cells Isolated on the Basis of Adherence. J Am Coll Cardiol (2017) 0.75
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2009) 27.89
Bone marrow cells regenerate infarcted myocardium. Nature (2001) 21.24
Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng (2001) 20.65
Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res (2008) 8.49
Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med (2003) 8.46
Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med (2005) 7.66
Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res (2009) 7.09
Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation (2004) 6.43
Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res (2004) 6.34
Myocardial substrate metabolism in the normal and failing heart. Physiol Rev (2005) 6.06
Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J (2006) 5.93
Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One (2008) 5.91
Regenerating the heart. Nat Biotechnol (2005) 5.58
Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol (2005) 4.67
Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol (2005) 4.57
The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res (2006) 4.38
Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ Res (2010) 4.19
Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res (2006) 4.14
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature (2002) 4.10
Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res Ther (2007) 3.97
Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance. Am J Physiol Heart Circ Physiol (2006) 3.78
Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci U S A (2007) 3.74
Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands, and cytokines. Circulation (2001) 3.50
Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation (2010) 3.42
Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol (2005) 3.40
Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation (2004) 3.26
Endothelial dysfunction. J Am Soc Nephrol (2004) 3.18
Autologous transplantation of bone marrow cells improves damaged heart function. Circulation (1999) 3.17
Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation (2005) 3.10
SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J (2007) 3.01
Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res (2007) 2.98
Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation (2009) 2.93
Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia. Circulation (2003) 2.82
Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A (2006) 2.75
Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiol Heart Circ Physiol (2004) 2.69
Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res (2009) 2.66
Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem (2009) 2.66
Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells (2007) 2.45
Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res (2000) 2.37
Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther (2008) 2.25
High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol Syst Biol (2009) 2.21
Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors. Anat Rec (2001) 2.18
Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation. J Mol Cell Cardiol (2008) 2.16
Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension (2005) 2.03
Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol (2006) 2.01
Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res (2008) 1.97
Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med (2007) 1.97
Wnt signaling controls the fate of mesenchymal stem cells. Gene (2008) 1.92
Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res (2005) 1.79
The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proc Natl Acad Sci U S A (2008) 1.77
Thymosin beta4 is an essential paracrine factor of embryonic endothelial progenitor cell-mediated cardioprotection. Circulation (2008) 1.77
Mesenchymal stem cells in arthritic diseases. Arthritis Res Ther (2008) 1.75
Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol (2005) 1.73
Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model. Stem Cells (2009) 1.71
Regeneration of infarcted myocardium by intramyocardial implantation of ex vivo transforming growth factor-beta-preprogrammed bone marrow stem cells. Circulation (2005) 1.70
Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res (2004) 1.65
Human bronchial fibroblasts exhibit a mesenchymal stem cell phenotype and multilineage differentiating potentialities. Lab Invest (2005) 1.61
Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res (2010) 1.60
Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells (2009) 1.60
Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions. FEBS Lett (2007) 1.60
Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin Biochem (2007) 1.57
Novel cell-free strategy for therapeutic angiogenesis: in vitro generated conditioned medium can replace progenitor cell transplantation. PLoS One (2009) 1.56
The effects of mesenchymal stem cells transduced with Akt in a porcine myocardial infarction model. Cardiovasc Res (2006) 1.56
Effect of hypoxia on gene expression of bone marrow-derived mesenchymal stem cells and mononuclear cells. Stem Cells (2007) 1.51
Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem Cells (2009) 1.50
Interleukin-10 from transplanted bone marrow mononuclear cells contributes to cardiac protection after myocardial infarction. Circ Res (2008) 1.50
Cardiac progenitor cell cycling stimulated by pim-1 kinase. Circ Res (2010) 1.46
VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physiol Heart Circ Physiol (2008) 1.44
Identification and functionality of proteomes secreted by rat cardiac stem cells and neonatal cardiomyocytes. Proteomics (2010) 1.38
Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair (2008) 1.37
Recent advances in protein and peptide drug delivery systems. Curr Drug Deliv (2007) 1.36
Hyaluronan mixed esters of butyric and retinoic Acid drive cardiac and endothelial fate in term placenta human mesenchymal stem cells and enhance cardiac repair in infarcted rat hearts. J Biol Chem (2007) 1.35
Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair. Cardiovasc Res (2007) 1.34
Profound bioenergetic abnormalities in peri-infarct myocardial regions. Am J Physiol Heart Circ Physiol (2006) 1.33
Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol Ther (2003) 1.33
New insights into paracrine mechanisms of human cardiac progenitor cells. Eur J Heart Fail (2010) 1.29
Preconditioning mesenchymal stem cells with transforming growth factor-alpha improves mesenchymal stem cell-mediated cardioprotection. Shock (2010) 1.28
Paracrine factors secreted by endothelial progenitor cells prevent oxidative stress-induced apoptosis of mature endothelial cells. Atherosclerosis (2010) 1.27
microRNAs in heart disease: putative novel therapeutic targets? Eur Heart J (2010) 1.27
Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res (2001) 1.26
Enrichment for STRO-1 expression enhances the cardiovascular paracrine activity of human bone marrow-derived mesenchymal cell populations. J Cell Physiol (2010) 1.26
Proteomics identifies thymidine phosphorylase as a key regulator of the angiogenic potential of colony-forming units and endothelial progenitor cell cultures. Circ Res (2008) 1.24
Capturing the stem cell paracrine effect using heparin-presenting nanofibres to treat cardiovascular diseases. J Tissue Eng Regen Med (2010) 1.23
Molecular and cell-based therapies for protection, rescue, and repair of ischemic myocardium: reasons for cautious optimism. Circulation (2004) 1.22
Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. J Mol Cell Cardiol (2006) 1.22
Release of proinflammatory mediators and expression of proinflammatory adhesion molecules by endothelial progenitor cells. Am J Physiol Heart Circ Physiol (2009) 1.20
Functional and bioenergetic modulations in the infarct border zone following autologous mesenchymal stem cell transplantation. Am J Physiol Heart Circ Physiol (2007) 1.20
Sphingosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac fibroblasts. Cardiovasc Res (2009) 1.18
Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction. Inflammation (2007) 1.18
Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. Mol Cells (2005) 1.16
Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton. J Cell Biochem (2010) 1.16
Secretome from mesenchymal stem cells induces angiogenesis via Cyr61. J Cell Physiol (2009) 1.16
Resident cardiac stem cells. Cell Mol Life Sci (2007) 1.10
SFRP2 regulates cardiomyogenic differentiation by inhibiting a positive transcriptional autofeedback loop of Wnt3a. Stem Cells (2007) 1.09
Improved function and myocardial repair of infarcted heart by intracoronary injection of mesenchymal stem cell-derived growth factors. J Cardiovasc Transl Res (2010) 1.09
Mesenchymal stem cells modified with stromal cell-derived factor 1 alpha improve cardiac remodeling via paracrine activation of hepatocyte growth factor in a rat model of myocardial infarction. Mol Cells (2009) 1.08
Direct injection of autologous mesenchymal stromal cells improves myocardial function. Biochem Biophys Res Commun (2009) 1.08
Embryonic stem cells attenuate myocardial dysfunction and inflammation after surgical global ischemia via paracrine actions. Am J Physiol Heart Circ Physiol (2008) 1.05
Effects of mesenchymal stem cell transplantation on extracellular matrix after myocardial infarction in rats. Coron Artery Dis (2005) 1.05
Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res (2008) 8.49
Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med (2003) 8.46
Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med (2005) 7.66
Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J (2006) 5.93
Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc Natl Acad Sci U S A (2007) 3.74
MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res (2012) 3.53
Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther (2006) 2.85
Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation (2003) 2.27
Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. Hypertension (2005) 2.03
An initiative in mentoring to promote residents' and faculty members' careers. Acad Med (2004) 1.95
Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension (2006) 1.91
Atherosclerosis 2005: recent discoveries and novel hypotheses. Circulation (2005) 1.87
Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell (2007) 1.72
Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation (2002) 1.67
Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res (2010) 1.60
Molecular genetics and genomics of heart failure. Nat Rev Genet (2004) 1.60
Microarray gene expression profiles in dilated and hypertrophic cardiomyopathic end-stage heart failure. Physiol Genomics (2002) 1.57
Exogenously administered secreted frizzled related protein 2 (Sfrp2) reduces fibrosis and improves cardiac function in a rat model of myocardial infarction. Proc Natl Acad Sci U S A (2010) 1.51
Cell cycle-dependent regulation of smooth muscle cell activation. Arterioscler Thromb Vasc Biol (2004) 1.51
Early beneficial effects of bone marrow-derived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem Cells (2009) 1.50
Essential role of ICAM-1/CD18 in mediating EPC recruitment, angiogenesis, and repair to the infarcted myocardium. Circ Res (2006) 1.46
Cytokine-induced mobilization of circulating endothelial progenitor cells enhances repair of injured arteries. Circulation (2004) 1.46
Dynamic tracking during intracoronary injection of 18F-FDG-labeled progenitor cell therapy for acute myocardial infarction. J Nucl Med (2007) 1.45
Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation (2004) 1.41
Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol (2002) 1.38
Improving the health of the community: Duke's experience with community engagement. Acad Med (2008) 1.38
Secreted frizzled related protein 2 protects cells from apoptosis by blocking the effect of canonical Wnt3a. J Mol Cell Cardiol (2008) 1.35
Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas' disease cardiomyopathy. Am J Pathol (2005) 1.32
Molecular and cell-based therapies for protection, rescue, and repair of ischemic myocardium: reasons for cautious optimism. Circulation (2004) 1.22
Vagal stimulation, through its nicotinic action, limits infarct size and the inflammatory response to myocardial ischemia and reperfusion. J Cardiovasc Pharmacol (2011) 1.21
Genetic engineering of mesenchymal stem cells and its application in human disease therapy. Hum Gene Ther (2010) 1.19
Perspective: global medicine: opportunities and challenges for academic health science systems. Acad Med (2011) 1.17
Heme-oxygenase-1-induced protection against hypoxia/reoxygenation is dependent on biliverdin reductase and its interaction with PI3K/Akt pathway. J Mol Cell Cardiol (2007) 1.15
Training the next generation of physician-executives: an innovative residency pathway in management and leadership. Acad Med (2011) 1.14
Liver X receptors alpha and beta regulate renin expression in vivo. J Clin Invest (2005) 1.13
SFRP2 regulates cardiomyogenic differentiation by inhibiting a positive transcriptional autofeedback loop of Wnt3a. Stem Cells (2007) 1.09
Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury. Proc Natl Acad Sci U S A (2004) 1.09
Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. FASEB J (2006) 1.09
Sex dependence and temporal dependence of the left ventricular genomic response to pressure overload. Physiol Genomics (2003) 1.06
Nuclear receptor LXRalpha is involved in cAMP-mediated human renin gene expression. Mol Cell Endocrinol (2004) 1.06
The angiotensin II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling. Mol Biol Cell (2003) 1.04
Construction of a zebrafish cDNA microarray: gene expression profiling of the zebrafish during development. Biochem Biophys Res Commun (2002) 1.01
Progenitor cell therapy in a porcine acute myocardial infarction model induces cardiac hypertrophy, mediated by paracrine secretion of cardiotrophic factors including TGFbeta1. Stem Cells Dev (2008) 1.01
Endothelium-targeted gene and cell-based therapies for cardiovascular disease. Arterioscler Thromb Vasc Biol (2004) 0.99
Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease. Circulation (2002) 0.98
Physiological genomics of cardiac disease: quantitative relationships between gene expression and left ventricular hypertrophy. Physiol Genomics (2006) 0.98
Identification of calcium-modulating cyclophilin ligand (CAML) as transducer of angiotensin II-mediated nuclear factor of activated T cells (NFAT) activation. J Biol Chem (2005) 0.96
Preemptive heme oxygenase-1 gene delivery reveals reduced mortality and preservation of left ventricular function 1 yr after acute myocardial infarction. Am J Physiol Heart Circ Physiol (2007) 0.95
Risk factor criteria. Circulation (2004) 0.95
Clustering and heritability of insulin resistance in Chinese and Japanese hypertensive families: a Stanford-Asian Pacific Program in Hypertension and Insulin Resistance sibling study. Hypertens Res (2002) 0.95
Potent endothelial progenitor cell-conditioned media-related anti-apoptotic, cardiotrophic, and pro-angiogenic effects post-myocardial infarction are mediated by insulin-like growth factor-1. Eur Heart J (2011) 0.95
Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, RhoA, and myocardin. Circ Res (2009) 0.94
Angiotensin type 2 receptor is expressed in murine atherosclerotic lesions and modulates lesion evolution. Circulation (2005) 0.94
Physiological genomics of human arteries: quantitative relationship between gene expression and arterial stiffness. Circulation (2003) 0.94
Adult renal mesenchymal stem cell-like cells contribute to juxtaglomerular cell recruitment. J Am Soc Nephrol (2013) 0.93
Transcription factor decoy. Circ Res (2002) 0.92
Abi3bp is a multifunctional autocrine/paracrine factor that regulates mesenchymal stem cell biology. Stem Cells (2013) 0.91
A global partnership in medical education between Duke University and the National University of Singapore. Acad Med (2008) 0.91
Genetic markers: progress and potential for cardiovascular disease. Circulation (2004) 0.91
Differential gene expression of blood-derived cell lines in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol (2004) 0.90
Chronic recurrent myocardial ischemic injury is significantly attenuated by pre-emptive adeno-associated virus heme oxygenase-1 gene delivery. J Am Coll Cardiol (2006) 0.90
Identification of a novel set of genes regulated by a unique liver X receptor-alpha -mediated transcription mechanism. J Biol Chem (2003) 0.89
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? Circulation (2004) 0.88
Enhancing stem cell therapy through genetic modification. J Am Coll Cardiol (2005) 0.88
Mesenchymal stem cells differentiate into renin-producing juxtaglomerular (JG)-like cells under the control of liver X receptor-alpha. J Biol Chem (2010) 0.88
Nasal vaccination with troponin reduces troponin specific T-cell responses and improves heart function in myocardial ischemia-reperfusion injury. Int Immunol (2009) 0.86
Elucidating the molecular mechanism of cardiac remodeling using a comparative genomic approach. Physiol Genomics (2003) 0.86
C3orf58, a novel paracrine protein, stimulates cardiomyocyte cell-cycle progression through the PI3K-AKT-CDK7 pathway. Circ Res (2013) 0.86
Chromosomal distribution of the human cardiovascular transcriptome. Genomics (2003) 0.85
Direct reprogramming of cardiac fibroblasts to cardiomyocytes using microRNAs. Methods Mol Biol (2014) 0.84
Evolving revascularization approaches for myocardial ischemia. Am J Cardiol (2003) 0.82
The unstoppable attraction for induced pluripotent stem cells: are they the magic bullet for modeling inherited arrhythmogenic diseases? J Am Coll Cardiol (2012) 0.81
Gene and cell-based therapies for heart disease. FASEB J (2004) 0.81
Molecular mechanism of juxtaglomerular cell hyperplasia: a unifying hypothesis. J Am Soc Hypertens (2010) 0.81
Combination of miRNA499 and miRNA133 exerts a synergic effect on cardiac differentiation. Stem Cells (2015) 0.81
Fostering creativity: how the Duke Graduate Medical Education Quasi-Endowment encourages innovation in GME. Acad Med (2013) 0.80
Potential for germ line transmission after intramyocardial gene delivery by adeno-associated virus. Biochem Biophys Res Commun (2004) 0.80
Genetic therapies for cardiovascular diseases. Trends Mol Med (2005) 0.79
Allogeneic lethally irradiated cord blood mononuclear cells in no-option critical limb ischemia: a "box of rain". Stem Cells Dev (2013) 0.78
Bioluminescence resonance energy transfer identify scaffold protein CNK1 interactions in intact cells. FEBS Lett (2005) 0.78
Targeted gene therapy for rat glomerulonephritis using HVJ-immunoliposomes. J Gene Med (2002) 0.78
Physiological genomics: implications in hypertension research. Hypertension (2002) 0.78
Angiotensin-converting enzyme insertion/deletion polymorphism and risk of restenosis after directional coronary atherectomy followed by stent implantation. Thromb Haemost (2004) 0.76
Angiotensin II type 1 receptor-associated protein is an endogenous inhibitor of angiotensin II type 1 receptor action in cardiac hypertrophy: role in check and balance. Hypertension (2010) 0.75
Separating the wheat from the chaff: focus on "in silico data filtering to identify new angiogenesis targets from a large in vitro gene profile data set". Physiol Genomics (2002) 0.75
Cardiovascular Research and the National Academy of Medicine: Advancing Progress in Science and Medicine: Part 1: Who We Are. Circ Res (2017) 0.75
Molecular approaches for the treatment of atherosclerosis. Cardiol Clin (2002) 0.75